Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MTOR | P42345 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141694 | 1.00 | LMNA (0.58) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL18402886 | 0.89 | LMNA (0.60) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL18499821 | 0.89 | LMNA (0.60) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL15186238 | 0.89 | LMNA (0.60) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL28633742 | 0.85 | LMNA (0.71) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7179484 | 0.83 | SLC28A1 (0.55) | SLC29A1 | |
| SCHEMBL7179495 | 0.83 | SLC28A1 (0.55) | SLC29A1 | |
| SCHEMBL15186172 | 0.82 | LMNA (0.60) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL18402896 | 0.82 | LMNA (0.60) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL14470877 | 0.76 | LMNA (0.45) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004512810-A | — | — | 2004-04-30 | — | — | JP | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2002512794-A | — | — | 2002-05-08 | — | — | JP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | claimed |
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6617438-B1 | Nucleic acid of given formula; ribozyme able to cleave RNA of HER2 gene; use as anticarcinogenic agent | SIRNA THERAPEUTICS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6528640-B1 | Of given formula; can use to inhibit HER2/neu/ ErbB2 gene expression; anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6482932-B1 | Nucleoside triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2002-11-19 | — | — | US | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | NTPCR, DNTT, RNGTT | LMNA 4394/4885MTOR 2203/4885THRB 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.